
11 Jun 2019
Melvyn’s story
In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.
“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.
“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.
“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”
Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.
“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.
“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.
“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”
Professor Francesco Dazzi
“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.
“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”
Related posts
19 June 2023
Leukaemia UK research paves the way for personalised lymphoma treatment
Despite promising trials, standard treatment for diffuse large B-cell lymphoma (DLBCL) hasn’t changed in a decade. New treatment strategies for this type of blood cancer are urgently needed. Could the…
31 October 2023
Chris Dew joins Leukaemia UK as Director of Finances & Resources
Leukaemia UK is delighted to announce the appointment of Chris Dew as Director of Finance & Resources, following ten years as Chief Financial Officer at musical therapy charity Nordoff-Robbins. The…
8 July 2025
The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care
The Best Practice Timed Pathway We’re delighted to share that Leukaemia UK, in partnership with Lymphoma Action and Myeloma UK, is working with the NHS England Cancer programme team to…
19 February 2024
Leukaemia UK launches new Patient Care Pioneer Award funding initiative
Leukaemia UK is delighted to launch a brand-new funding scheme in 2024, intended specifically for innovative, patient-focussed applied research and targeting UK-based healthcare professionals. The first of its kind for…